Application for PRECISEU Best Practice Recognition – Your Excellence Deserves Recognition!

Application for PRECISEU Best Practice Recognition – Your Excellence Deserves Recognition!

Apply now for the second Edition of the PRECISEU Best Practice Recognition!

The PRECISEU Best Practice Recognition is more than a contest—it is a movement to accelerate the future of personalised medicine across Europe. Born from the PeRsonalised medicine Empowerment Connecting Innovation ecoSystems across EUrope (PRECISEU) programme, this visionary initiative shines a spotlight on pioneers who are translating cutting-edge science into realworld care—especially through the innovative and responsible use of health data. With ambitious purpose it celebrates exemplary practices that not only push the boundaries of what’s possible but also make these breakthroughs accessible, equitable, and impactful for all. This recognition is a catalyst for transformation—bridging science and society, innovation and implementation, vision and care. It calls upon researchers, entrepreneurs, institutions, and citizens alike to lead with purpose, collaborate boldly, and ensure that life-changing therapies reach every patient, everywhere—fast and fair. PRECISEU Best Practice Recognition honours not just innovation, but the courage to act, the will to include, and the power to change lives.

The call is now open for the second Edition

We offer three more sessions where we explain how to apply:

Info session 1: 12 December 2025, 1:30 – 2:30 pm – register here

Info session 2: 8 January 2026  1:30 – 2:30 pm – register here

Info session 3: 6. February 2026, 1:30 – 2:30 pm – register here

Find a preview to the questionnaire to be filed here. 

Call deadline March 1st 2026. Apply here. 

 Useful links

register now

Our latest News

discover more
New bioRN Members of 2025

New bioRN Members of 2025

In 2025, the bioRN cluster experienced a strong and dynamic expansion as many new members joined its growing network. This influx of new companies and institutions further strengthened the cluster’s expertise, diversity, and innovative power. The cluster is now pleased to introduce these new members and highlight the diverse capabilities they bring, further reinforcing its […]

ariadne.ai Secures Invest BW Funding to Build “TumorTwin”: The First Digital Twin for Glioblastoma Powered by Morphometric Spatial Multi-Omics

ariadne.ai Secures Invest BW Funding to Build “TumorTwin”: The First Digital Twin for Glioblastoma Powered by Morphometric Spatial Multi-Omics

HEIDELBERG, Germany – January 9, 2026 – ariadne.ai (Germany) GmbH today announced it has been awarded €518,000 in non-dilutive funding from the State of Baden- Württemberg (Invest BW) for its ambitious new project, TumorTwin. The project aims to revolutionize the treatment of Glioblastoma, one of the deadliest and most aggressive brain tumors, by creating a […]

AMGEN acquires Dark Blue Therapeutics, bolstering oncology pipeline

AMGEN acquires Dark Blue Therapeutics, bolstering oncology pipeline

Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million.   The acquisition adds to Amgen’s […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp